The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance. This FDA clearance will ensure that ...
Roche (RHHBY) announced that its cobas 6800/8800 systems – two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which ...
- With the new cobas EBV and cobas BKV Tests on the cobas 6800/8800 Systems, healthcare professionals can now determine which transplant patients are at risk of further complications caused by ...
The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world.
The fully automated systems offer the fastest time to results, the highest throughput and the longest walk-away time available among automated molecular platforms, providing laboratories both improved ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for the cobas® HIV-1 viral load test by the United States Food and Drug Administration (FDA) for use on the cobas® ...
Swiss biotech company Roche announced on December 21, 2015 that the FDA has approved the Cobas® 6800 and 8800 Systems from its Pleasanton, California-based Roche Molecular Diagnostics (RMD) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results